These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22081481)

  • 1. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
    Pan CY; Yang W; Tou C; Gause-Nilsson I; Zhao J
    Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
    Yang W; Pan CY; Tou C; Zhao J; Gause-Nilsson I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
    Rosenstock J; Aguilar-Salinas C; Klein E; Nepal S; List J; Chen R;
    Curr Med Res Opin; 2009 Oct; 25(10):2401-11. PubMed ID: 19650754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
    Hollander P; Li J; Allen E; Chen R;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL; Li J; Frederich R; Allen E; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
    Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
    Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
    Kania DS; Gonzalvo JD; Weber ZA
    Clin Ther; 2011 Aug; 33(8):1005-22. PubMed ID: 21802144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
    Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
    Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E; Bryzinski B; Hirshberg B; Cook W
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
    Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM
    Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
    Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
    Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.